DURHAM, N.C., Dec. 9, 2010 (GLOBE NEWSWIRE) — Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) second quarter ended October 31, 2010.
Highlights (activity through December 9, 2010)
Received 5,000 grant under the Patient Protection and Affordable [...] http://bit.ly/fQ9dzx
No comments:
Post a Comment